- Home
- LI vs ASND Comparison
LI vs ASND Comparison
Compare LI & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LI | ASND |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | China | Denmark |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 15.2B |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LI | ASND |
|---|---|---|
| Price | $12.34 | $248.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 16 |
| Target Price | $19.66 | ★ $281.50 |
| AVG Volume (30 Days) | ★ 3.4M | 484.0K |
| Earning Date | 05-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.98 | $96.35 |
| Revenue Next Year | $22.72 | $44.91 |
| P/E Ratio | $29.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.65 | $186.05 |
| 52 Week High | $26.94 | $282.15 |
Technical Indicators
Market Signals| Indicator | LI | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 41.51 | 42.01 |
| Support Level | $12.06 | $236.82 |
| Resistance Level | $12.39 | $248.31 |
| Average True Range (ATR) | 0.29 | 7.53 |
| MACD | -0.05 | -0.63 |
| Stochastic Oscillator | 4.85 | 25.10 |
Price Performance
Historical ComparisonAbout LI Li Auto Inc.
Li Auto is one of China's leading new energy vehicle manufacturers. Founded in 2015, the company designs, develops, manufactures, and sells premium smart NEVs with a particular focus on family size premium SUVs and MPVs. Li Auto started volume production of its first model—the Li One, an SUV that is a premium plug-in electric vehicle- in November 2019. Besides PHEVs, its product portfolio now extends to EVs that are fully battery-powered, reaching a wide audience. It has sold over 400,000 NEVs in 2025, accounting for about 3% of China's passenger NEV market.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.